Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells

Yuta Mizuno, Hsi Chang, Katsutsugu Umeda, Akira Niwa, Toru Iwasa, Tomonari Awaya, So Ichiro Fukada, Hiroshi Yamamoto, Shinya Yamanaka, Tatsutoshi Nakahata, Toshio Heike

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6+ cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.

Original languageEnglish
Pages (from-to)2245-2253
Number of pages9
JournalFASEB Journal
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 2010
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
Muscle Cells
Muscle
Skeletal Muscle
Stem Cells
Transplantation
Inbred mdx Mouse
Toxicity Tests
Pluripotent Stem Cells
Preclinical Drug Evaluations
Muscular Dystrophies
Embryonic Stem Cells
Drug-Related Side Effects and Adverse Reactions
Flow Cytometry
Muscles
Antibodies
Sorting
Therapeutics
Toxicity

Keywords

  • Duchenne muscular dystrophy
  • High engraftment efficiency
  • Long-term engraftment
  • No teratoma formation
  • Pax7

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Genetics
  • Molecular Biology

Cite this

Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. / Mizuno, Yuta; Chang, Hsi; Umeda, Katsutsugu; Niwa, Akira; Iwasa, Toru; Awaya, Tomonari; Fukada, So Ichiro; Yamamoto, Hiroshi; Yamanaka, Shinya; Nakahata, Tatsutoshi; Heike, Toshio.

In: FASEB Journal, Vol. 24, No. 7, 07.2010, p. 2245-2253.

Research output: Contribution to journalArticle

Mizuno, Y, Chang, H, Umeda, K, Niwa, A, Iwasa, T, Awaya, T, Fukada, SI, Yamamoto, H, Yamanaka, S, Nakahata, T & Heike, T 2010, 'Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells', FASEB Journal, vol. 24, no. 7, pp. 2245-2253. https://doi.org/10.1096/fj.09-137174
Mizuno, Yuta ; Chang, Hsi ; Umeda, Katsutsugu ; Niwa, Akira ; Iwasa, Toru ; Awaya, Tomonari ; Fukada, So Ichiro ; Yamamoto, Hiroshi ; Yamanaka, Shinya ; Nakahata, Tatsutoshi ; Heike, Toshio. / Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. In: FASEB Journal. 2010 ; Vol. 24, No. 7. pp. 2245-2253.
@article{0d1b0baa784648c58632952b451c9710,
title = "Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells",
abstract = "Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6+ cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.",
keywords = "Duchenne muscular dystrophy, High engraftment efficiency, Long-term engraftment, No teratoma formation, Pax7",
author = "Yuta Mizuno and Hsi Chang and Katsutsugu Umeda and Akira Niwa and Toru Iwasa and Tomonari Awaya and Fukada, {So Ichiro} and Hiroshi Yamamoto and Shinya Yamanaka and Tatsutoshi Nakahata and Toshio Heike",
year = "2010",
month = "7",
doi = "10.1096/fj.09-137174",
language = "English",
volume = "24",
pages = "2245--2253",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "7",

}

TY - JOUR

T1 - Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells

AU - Mizuno, Yuta

AU - Chang, Hsi

AU - Umeda, Katsutsugu

AU - Niwa, Akira

AU - Iwasa, Toru

AU - Awaya, Tomonari

AU - Fukada, So Ichiro

AU - Yamamoto, Hiroshi

AU - Yamanaka, Shinya

AU - Nakahata, Tatsutoshi

AU - Heike, Toshio

PY - 2010/7

Y1 - 2010/7

N2 - Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6+ cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.

AB - Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6+ cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.

KW - Duchenne muscular dystrophy

KW - High engraftment efficiency

KW - Long-term engraftment

KW - No teratoma formation

KW - Pax7

UR - http://www.scopus.com/inward/record.url?scp=77954448510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954448510&partnerID=8YFLogxK

U2 - 10.1096/fj.09-137174

DO - 10.1096/fj.09-137174

M3 - Article

VL - 24

SP - 2245

EP - 2253

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 7

ER -